We are live on ! Find out more
GRCE icon

Grace Therapeutics
GRCE

10 hedge funds and large institutions have $1.06M invested in Grace Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,214% more capital inflows, than outflows

Capital inflows: $53.9K | Capital outflows: $1.63K

25% more funds holding

Funds holding: 8 → 10 (+2)

0.23% more ownership

Funds ownership: 3.66% → 3.89% (+0.23%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu KCG Holdings
Virtu KCG Holdings
New York
+$45K
2
Renaissance Technologies
Renaissance Technologies
New York
+$6.96K
3
UBS Group
UBS Group
Switzerland
+$1.63K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$370

Top Sellers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$888
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$740

GRCE Hedge Fund Activity: Q3 2016 in Review

10 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2016, worth a combined $1.06M — up 35% from $784K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new GRCE positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $45K. The largest seller was Toronto Dominion Bank, cutting an estimated $888.

  • 10 institutional investors held Grace Therapeutics (GRCE) as of Q3 2016, up from 8 in Q2 2016.
  • Funds reported $1.06M of Grace Therapeutics stock for Q3 2016, up 35% quarter-over-quarter.
  • 2 funds opened new Grace Therapeutics positions in Q3 2016 and 0 closed out, a net change of +2 holders.
  • The largest Grace Therapeutics buyer in Q3 2016 was Virtu KCG Holdings, an estimated $45K added.
  • The largest Grace Therapeutics seller in Q3 2016 was Toronto Dominion Bank, an estimated $888 sold.

Based on aggregated 13F filings for Q3 2016.